Market Trends of Hematology Analyzers Industry
This section covers the major market trends shaping the Hematology Analyzers Market according to our research experts:
3 Part Hematology Analyzer is the Segment by Instruments Expected to Hold Significant Market Share Over the Forecast Period
A 3-part differential cell counter uses Coulter's Principle to find the size and volume of the cell. The sample is lysed and dissolved into an electrolyte solution in a container, which also holds a smaller container. 3-part hematology analyzer systems are ideally suited for physician office laboratories, clinics, and small hospitals that perform moderately complex testing. There is increased interest in 5-part hematology analyzers, however, 3-part hematology analyzers are more cost-effective for routine hematological tests. Furthermore, with advancements in technology and the availability of these instruments across the world coupled with affordability the market is projected to have notable growth. Similarly, convenience and accurate results are the two major reasons driving the growth of the segment over the forecast period.
Ebola Virus is a serious fatal condition that is caused by 4 different species of virus in human and non-human primates. The virus can spread to people through direct contact with the blood, and body fluids, of the person who is having or died from the Ebola virus. It causes hemorrhagic fever which leads to internal and external bleeding and affects multiple organs. The Ebola outbreak in Uganda was declared on September 20, 2022, and it has already spread to seven regions (Kasanda, Kyegegwa, Bunyangabu, and Kagadi districts beyond the original epicenter in Mubende district, and then to Kampala City and Wakiso). Thus, such outbreaks require proper diagnosis to control the spread of the disease which is expected to increase the demand for 3 part hematology analyzer during the forecast period.
Initiatives such as product launches are another factor in market growth. For instance, in April 2022 Sysmex Europe launched its new three-part differential automated hematology analyzer, XQ-320. It is a robust device with low demands for sample volume, bench space, and maintenance in Europe. Thus, the abovementioned factors are expected to increase market growth during the forecast period.
North America is Expected to Hold Significant Market Share Over the Forecast Period
The market for hematology analyzers in the North American region is growing at a steady pace. This can be attributed to the increasing burden of blood disorders and the growth in the adoption of hematology analyzers by the diagnostic industry. For instance, according to the American Society of Hematology, anemia, which is a common disorder, affects more than three million Americans, particularly women of 'childbearing age. According to the Leukemia and Lymphoma Society in 2021, every three minutes, a person in the United States is diagnosed with blood cancer. An estimated 186,400 people in the United States were diagnosed with leukemia, lymphoma, or melanoma in 2021.
Furthermore, many centers in the state are international leaders in the diagnosis and treatment of blood diseases and collaborate in many research projects to improve diagnosis and treatment options for blood diseases. Many market players are present in the country and are continuously focusing on the development and introduction of novel products. In February 2021 Beckman Coulter launched the DxH 560 AL, a tabletop hematology analyzer designed to reduce time and resource constraints faced by small- to mid-sized laboratories. Similarly, in November 2021, Avricore Health Inc signed a non-exclusive pilot supplier distribution agreement in Canada between HealthTab Inc., a wholly-owned subsidiary, and Abbott, the global healthcare company, concerning the handheld blood chemistry analyzer i-STAT Alinity. Thus, such product launches are expected to increase the adoption of hematology analyzers in the region.
These factors drive the demand for hematology analyzers in the North American region over the forecast period.
